Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients
British Journal of Haematology · 2023
DOI: 10.1111/bjh.19140 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Hailing Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, P…. Hauptthemen laut MEDLINE: Lymphoma, Hepatitis B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project.
Abstract (Originalsprache)
This study aimed to investigate a stratified approach based on hepatitis B virus (HBV) surface antibody (anti‐HBs) for managing HBV reactivation (HBVr) in lymphoma patients with serological protection against HBV. A retrospective analysis was conducted on 209 lymphoma patients with a baseline anti‐HBs titre of ≥10 iu/L, who were either positive or negative for HBV core antibody (anti‐HBc). The results revealed that 15.7% of patients lost serological protection following 6‐month anti‐lymphoma therapy. With a median follow‐up of 28.1 months, the cumulative rates of HBVr at 6 months, 2 years and 4 years were 2.9%, 4.7% and 6.3% respectively. Without intervention, the overall rate of reactivation was 2.0% for patients with isolated anti‐HBs and 10.5% for those with positive anti‐HBs and anti‐HBc. To identify patients at high risk of losing seroprotection and susceptible to HBVr, a predictive model was developed. The high‐risk group had significantly higher rates of serological protection loss (27.8% vs. 2.2%) and cumulative incidence of HBVr (22.0% vs. 0%) compared to the low‐risk group. Overall, this study highlights the risk of HBVr in lymphoma patients with positive anti‐HBs, with or without positive anti‐HBc, and recommends periodic monitoring for low‐risk patients and early intervention for high‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personali…
- Department of Geriatric, Nanjing Second Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
ORCID-Profile: Jianyong Li, Lei Cao, Lei Fan
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Liu, H., He, Z., Gui, R., Guo, J., Chen, L., Zhong, M., Li, J., Cao, L., & Fan, L. (2023). Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients. British Journal of Haematology. https://doi.org/10.1111/bjh.19140
Vancouver
Liu H, He Z, Gui R, Guo J, Chen L, Zhong M, et al. Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients. British Journal of Haematology. 2023. doi:10.1111/bjh.19140
BibTeX
@article{Liu2023,
author = {Liu, Hailing and He, Zhen and Gui, Renfu and Guo, Jingjing and Chen, Lvwen and Zhong, Miao and Li, Jianyong and Cao, Lei and Fan, Lei},
title = {Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.19140}
}
EUVIMED